LSIPR 50 2018: Kush Parmar
Name: Kush Parmar
Organisation: 5AM Ventures
Position: Managing Partner
A graduate of Princeton and Harvard University, Kush Parmar is managing partner of early-stage venture capital firm 5AM Ventures.
Established in 2002, 5AM Ventures focuses on building next-generation life sciences companies. It has approximately $1 billion under management and has offices in California and Massachusetts.
5AM Ventures’ portfolio includes Bellerophon Therapeutics, Alexza Pharmaceuticals and Cleave Biosciences.
Aside from leading investments, the business prides itself on being directly involved in the businesses it invests in with regard to company strategy, management recruiting, business developing and fundraising.
Parmar joined 5AM Ventures in 2010 from Harvard Medical School, where he was a National Institute of Health-sponsored medical degree/PhD physician scientist fellow in the Harvard-MIT health sciences and technology programme.
Parmar serves on the advisory board of Penn Medicine, Princeton University’s department of molecular biology and the Grace Science Foundation.
Prior to joining 5AM Ventures in 2010, Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. He also worked on developmental genetics at Princeton University alongside Eric Wieschaus—winner of the Nobel Prize in Medicine in 1995.
Parmar holds an AB in molecular biology and mediaeval studies from Princeton University, a PhD in experimental pathology from Harvard University and an MD from Harvard Medical School.
